Phase IaIb Study of ROSE12 with or without Atezolizumab or Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors
Led by Chugai Pharmaceutical · Updated on 2026-07-28
209
Participants Needed
14
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase IaIb open-label study to evaluate the safety and pharmacokinetics of ROSE12 alone and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study includes three parts dose escalation, biopsy for biomarker evaluation, and expansion in selected tumor types. The goal is to find the maximum tolerated dose and recommended dose, as well as to assess safety and preliminary anti-tumor activity.
Participants will receive ROSE12 as an intravenous infusion at increasing doses, either alone or combined with atezolizumab or pembrolizumab, also given by intravenous infusion. Serial biopsies will be performed in some parts to study biomarkers. The study consists of multiple parts including dose-escalation phases, biopsy phases, and expansion phases where patients receive recommended doses of the drug combinations.
During the study, participants will have safety and tolerability monitored from screening through treatment and follow-up, for up to approximately 43 months. Researchers will measure pharmacokinetics by monitoring serum concentrations of the drugs and assess preliminary anti-tumor effects. Biomarker evaluations and immunogenicity assessments will also be conducted. Participants will have regular visits for infusions, biopsies, and safety assessments throughout the study period.
CONDITIONS
Brief Title
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Research Team
C
Clinical trials information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
ROSE12 regimen
Standard chemotherapy
What it is
An experimental antibody called ROSE12, designed to selectively deplete regulatory T cells in tumors by binding CTLA‑4 only in high‑ATP environments, being tested alone or with atezolizumab or pembrolizumab in a sequential Phase I solid tumor study
Standard chemotherapy regimens are commonly used as later‑line treatment options for patients with ICI‑refractory NSCLC or colorectal cancer
Role in trial
Investigational treatment being evaluated sequentially in dose‑escalation, biopsy and expansion parts including ICI‑refractory solid tumors
Not studied in this trial; represents current treatment outside the study
Primary use
Evaluated for safety, tolerability, pharmacokinetics and preliminary anti‑tumor activity in patients with advanced solid tumors including ICI‑refractory NSCLC/CRC
Used as later‑line anti‑cancer treatment aiming to reduce tumor burden where prior immunotherapy has failed
How it is given or performed
Given as an intravenous infusion alone or combined with IV atezolizumab or pembrolizumab, across multiple Parts including dose escalations, biopsies and expansion cohorts
Administered via standard intravenous chemotherapy regimens (e.g., platinum‑based agents), per routine oncology practice
Evidence status
Evidence limited to early Phase I investigation and preclinical models; human efficacy not yet established
Chemotherapy has established efficacy in later‑line treatment of ICI‑refractory NSCLC/CRC, per clinical practice
Important risks
Unknown in humans; potential risks include adverse events observed in early‑phase trials and immunotherapy combinations
Known toxicity profile including hematologic, gastrointestinal and organ‑specific side effects typical of chemotherapy
Important limitations
Phase I design with small, sequential cohorts; lacks control arm and results in ICI‑refractory solid tumors are preliminary
Limited effectiveness in heavily pretreated, ICI‑refractory patients and potential cumulative toxicity
Patient impact
Not yet established; human outcomes not available
Chemotherapy may offer tumor control and symptom relief in some patients, based on prior clinical use
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Age 18 years or older at time of signing informed consent
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate hematologic and organ function
Life expectancy of at least 12 weeks
Histologic confirmation of locally advanced or metastatic solid tumor
Refractory or resistant to standard therapies or no standard therapies available (for dose-escalation and biopsy parts)
Availability of fresh or representative tumor specimens (for dose-escalation and expansion parts)
Accessible lesion(s) for biopsy (for biopsy parts)
Diagnosis of immune checkpoint inhibitor-refractory 2L-3L non-small-cell lung cancer or 3L+ colorectal cancer (for expansion parts)
You will not qualify if you...
Clinically significant cardiovascular or liver disease
Treatment with investigational or anti-cancer therapy within 28 days prior to study drug
History of immune-mediated Grade 4 adverse events from prior cancer immunotherapy (excluding certain asymptomatic enzyme elevations)
Unresolved immune-related adverse events from prior immunotherapy except stable or managed conditions
Unresolved adverse events from prior anti-cancer therapy above Grade 1 except alopecia, vitiligo, or managed endocrinopathy
Primary central nervous system malignancy or active untreated CNS metastases requiring treatment
Uncontrolled tumor-related pain
Uncontrolled pleural, pericardial effusion, or ascites needing recurrent drainage
Active or history of significant autoimmune disease
History of severe allergic or hypersensitivity reactions to antibodies or fusion proteins
Other malignancies within 5 years prior to study start (for expansion part)
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Dose Escalation and Biopsy
Duration - Up to 43 months
Participants receive ROSE12 alone or in combination with atezolizumab or pembrolizumab by intravenous infusion at increasing doses. Serial biopsies may be conducted to evaluate biomarkers.
Regular visits for infusions and assessments
Expansion
Duration - Up to 43 months
Participants receive ROSE12 combined with atezolizumab or pembrolizumab at recommended doses to further assess safety and preliminary anti-tumor activity.
Regular visits for infusions and assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
6
Similar Trials
Phase I Study to Find the Best Dose of 5-Azacitidine with PD-1PD-L1 Inhibitors for Patients With Tumors Resistant to These Treatments
Using 68Ga-MY6349 PETCT to Detect Trop-2 Expression in Solid Tumors Compared to 18F-FDG PETCT
Open Label Phase 12 Study of HRS-8364 Tablets for Treating Advanced Solid Tumors
Phase 12a Study of Intratumoral T3011 Alone and with Intravenous Pembrolizumab for Advanced or Metastatic Solid Tumors
Open-Label Phase I Study Evaluating Safety, Tolerability, and Pharmacokinetics of SHR-4595 Injection in Adults with Advanced Solid Tumors
Phase I Study Evaluating Safety, Tolerability, and Pharmacokinetics of SHR-4685 in Adults With Advanced Solid Tumors
Phase 1 Study of SHR-A1811 Subcutaneous Injection to Assess Safety, Pharmacokinetics, and Effectiveness in Adults with Solid Tumors
Phase IIIa Study of 177LuLu-SN201 for Safety and Early Effectiveness in Adults with Advanced or Treatment-Resistant Solid Tumors
Phase 1 Study of PTX-912 Given by IV Infusion in Adults With Advanced or Metastatic Solid Tumors
A Phase I Study of BB-1705 Given by Intravenous Infusion for Locally Advanced or Metastatic Solid Tumors
Assessing Safety, Tolerability, Pharmacokinetics, and Early Anti-Tumor Effects